Nature Communications (Jan 2020)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

  • Timothy P. Sheahan,
  • Amy C. Sims,
  • Sarah R. Leist,
  • Alexandra Schäfer,
  • John Won,
  • Ariane J. Brown,
  • Stephanie A. Montgomery,
  • Alison Hogg,
  • Darius Babusis,
  • Michael O. Clarke,
  • Jamie E. Spahn,
  • Laura Bauer,
  • Scott Sellers,
  • Danielle Porter,
  • Joy Y. Feng,
  • Tomas Cihlar,
  • Robert Jordan,
  • Mark R. Denison,
  • Ralph S. Baric

DOI
https://doi.org/10.1038/s41467-019-13940-6
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 14

Abstract

Read online

Remdesivir (RDV) is a broad-spectrum antiviral drug with activity against MERS coronavirus, but in vivo efficacy has not been evaluated. Here, the authors show that RDV has superior anti-MERS activity in vitro and in vivo compared to combination therapy with lopinavir, ritonavir and interferon beta and reduces severe lung pathology.